http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101413846-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 |
| filingDate | 2012-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2014-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2014-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101413846-B1 |
| titleOfInvention | The Liquified composition comprising of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide compound |
| abstract | The present invention provides a stable microemulsion liquid composition of celecoxib having a celecoxib as an active ingredient and comprising as a solvent diethylene glycol monoethyl ether or a mixed solvent of diethylene glycol monoethyl ether and propylene glycol monocaprylate , Macrogol 15 hydroxystearate or macrogol 15 hydroxystearate as a surfactant and caprylocaproyl polyoxyglyceride as a surfactant. The celecoxib microemulsion liquid composition according to the present invention improves the dissolution rate of the poorly soluble drug celecoxib formulation, so that the drug can be easily absorbed, the bioavailability can be increased, the AUC (absorption amount) can be significantly increased, By significantly shortening the expression time (Tmax), the pharmaceutical efficacy can be rapidly developed, and the pharmaceutical agent with greatly improved stability of the preparation in vitro can be produced, and the pharmaceutical effect equivalent to or higher than that of the conventional agent can be expressed with a small dosage. |
| priorityDate | 2012-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 85.